TriSalus draws $10M from OrbiMed credit facility upon hitting $30M revenue milestone

TriSalus Life Sciences, Inc.

$10 million drawdown under $50M credit agreement with OrbiMed triggered by achievement of $30M trailing 12-month product revenue milestone as of Jan 31, 2025.
Total drawn under the facility now $35 million; $15 million remains available.
Proceeds provide additional liquidity for ongoing operations and development programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.